Boehringer Ingelheim Acquires All ViraTherapeutics Shares To Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics ViraTherapeutics will operate in Innsbruck, Austria ...
